Navigation Links
Insulet Corporation to Report Fourth Quarter and Full Year 2007 Financial Results on Monday, March 17
Date:2/20/2008

BEDFORD, Mass., Feb. 20 /PRNewswire-FirstCall/ -- Insulet Corporation, (Nasdaq: PODD), the leader in wearable insulin pump technology with its OmniPod(R) Insulin Management System, announced plans to release its financial results for the fourth quarter and full year 2007 on Monday, March 17, 2008 after the close of the financial markets.

Insulet will also host a conference call at 8:00 a.m. Eastern Time on Tuesday, March 18, 2008 to discuss its fourth quarter and full year 2007 financial results. During the conference call, material information concerning the Company, its operations, strategies and prospects may be discussed.

To listen to the conference call, please dial 866.314.5232 for domestic callers and 617.213.8052 for international callers. The passcode is 86189075. A replay of the conference call will be available two hours after the start of the call through April 18, 2008 by dialing 888-286-8010 (domestic) and 617-801-6888 (international), passcode 17622814. An online archive of the conference call will also be available by accessing the Investor Information section of the company's website at http://investors.insulet.com.

About Insulet Corporation

Insulet Corporation is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use parts with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. Founded in 2000, Insulet is based in Bedford, MA.

Contact:

Stephanie Marks for Insulet Corporation

ir@insulet.com

877-PODD-IR1 (877-763-3471)


'/>"/>
SOURCE Insulet Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
2. Pharmion Corporation Announces 2007 Operating Results
3. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
4. VLST Corporation Announces Board and Executive Management Appointments
5. AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER(R) Duct Occluder II
6. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
7. LifeCell Corporation Revises Full Year 2007 Preliminary Results and Schedules Fourth Quarter 2007 Financial Results Conference Call; February 27, 2008 at 10:00 a.m. Eastern
8. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
9. Digirad Corporation to Receive Frost & Sullivan 2007 North American Award for Product Strategy
10. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
11. DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  Protagonist Therapeutics, Inc. ... on its oral peptide drug candidates, PTG-100 and ... the European Crohn,s and Colitis Organization (ECCO).  The ... Barcelona, Spain from February 15 – ... preclinical data on Protagonist drug candidates PTG-100 and ...
(Date:2/16/2017)... WEST PALM BEACH, Fla. , Feb. 16, ... molecular diagnostics company revolutionizing the development of liquid ... that it has entered into an exclusive license ... who will distribute MDNA,s proprietary liquid biopsy test ... in South Korea . This ...
(Date:2/16/2017)... , February 16, 2017 ... the infusion of innovative telemedicine application, new and ... that are experiencing a boom worldwide. The healthcare ... advancement of technologies, services and new therapies for ... RQHTF) (TSX-V: RHT), Cellectar Biosciences, Inc. (NASDAQ: ...
(Date:2/16/2017)... , Feb. 16, 2017  Windtree Therapeutics, Inc. ... focusing on developing aerosolized KL4 surfactant therapies for ... preclinical influenza study showed that aerosolized KL4 surfactant ... a well-established preclinical animal model. The Company believes ... body of evidence that supports the role of ...
Breaking Biology Technology:
(Date:2/2/2017)... YORK , Feb. 2, 2017  EyeLock LLC, ... released a new white paper " What You Should ... The problem of ensuring user authenticity is a growing ... the authentication of users. However, traditional authentication schemes such ... Biometric authentication offers an elegant solution ...
(Date:1/30/2017)... Jan. 30, 2017   Invitae Corporation (NYSE: ... genetic information companies, today announced that it will report ... provide 2017 guidance on Monday, February 13, 2017, and ... day at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... will briefly review financial results, guidance, and recent developments ...
(Date:1/24/2017)... Biopharm Reports has carried out a ... nuclear magnetic resonance spectroscopy (NMR). This involved the ... practices, developments, trends and end-user plans over the ... opportunities. These areas include growth in the use ... innovation requirements, hyphenated NMR techniques, main suppliers of ...
Breaking Biology News(10 mins):